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REVIEWS AND COMMENTARY • REVIEW
O
steoarthritis (OA) is a highly prevalent, disabling, and 
costly condition that has been recognized by the Unit-
ed States Food and Drug Administration as a serious dis-
ease with unmet medical need (1–3). OA is understood as 
a disease of the whole joint, involving structural damage 
of the articular cartilage, subchondral bone, ligaments, 
capsule, synovial membrane, and periarticular muscles 
(4,5). Pain is the predominant symptom and is a major 
driving force in clinical decision making and health ser-
vice attention (6).
Current management of OA is primarily focused on 
symptom control. Intra-articular corticosteroid (IACS) in-
jections are often used for pain management of hip and knee 
OA in patients who have not responded to oral or topical 
analgesics and are frequently intended to delay total joint 
replacement surgery if patients are young or hesitant to un-
dergo surgery right away (7). A recent case series presented 
data on possible negative outcomes of IACS injection as 
perceived from a radiologic perspective (8). These findings 
included accelerated OA progression, subchondral insuffi-
ciency fracture, complications of pre-existing osteonecrosis, 
and rapid joint destruction including bone loss. Another 
recent uncontrolled retrospective observational study that 
focused on IACS injection of the hip and subsequent joint 
events reported that almost half of the patients treated with 
IACS injections exhibited signs of radiographic progression 
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tent intense pain (10). A so-called structure-symptom discor-
dance in OA is recognized, wherein some patients with severe 
knee pain have minimal radiographic abnormalities and vice 
versa. For example, in the OA Initiative study only 9% of 
hips in patients with frequent pain showed radiographic hip 
OA, and 24% of hips with radiographic hip OA were fre-
quently painful (11). Such observations highlight the com-
plex, subjective, and multifactorial nature of pain in OA. If 
the between-person differences in knee pain are adequately 
controlled, a strong structure-symptom relationship can be 
observed (12). MRI data obtained in OA cohorts suggest that 
bone marrow edema, synovitis, and effusions appear to have 
the strongest relation to pain in OA (13). These structural 
pathologic lesions therefore provide rational therapeutic tar-
gets for addressing both structural pathology as well as the 
symptoms of disease. However, the success of treatments tar-
geting these lesions have had mixed results to date and/or 
only short-term benefit in clinical trials (14–17).
Given the lack of disease-modifying agents to date, treatment 
guidelines have largely focused on an algorithmic approach to 
OA pain management. Guidelines typically recommend weight 
loss; exercise; self-management approaches; and pharmacologic 
options that include topical nonsteroidal anti-inflammatory 
drugs, oral therapies (eg, nonsteroidal anti-inflammatory drugs), 
and intra-articular therapies as appropriate for a patient’s clinical 
circumstances, comorbidities, and/or contraindications (18–20).
Recent guidelines have recognized the potential utility of 
providing local therapy, such as topical nonsteroidal anti-inflam-
matory drugs, preferentially as initial therapy to spare systemic 
exposure to oral therapies that may have an unfavorable adverse-
effect profile or in patients with comorbid conditions where oral 
nonsteroidal anti-inflammatory drugs may be contraindicated 
(19,20). Intra-articular therapies in OA have traditionally been 
reserved for later stages in the treatment algorithm after topical 
and oral therapies have proven insufficient (18).
Treatment Recommendations
Several professional societies whose members treat patients 
with OA have formally evaluated IACS injections for inclu-
sion in their OA treatment guidelines. The methods for guide-
line development differed somewhat by society but started 
in each case with a systematic review of literature on IACS 
injections in OA, which provided the foundation for each 
society’s final recommendation. IACS treatment guidelines of 
four professional societies—the American Association of Or-
Abbreviations
IACS = intra-articular corticosteroid, OA = osteoarthritis
Summary
Intra-articular corticosteroid (IACS) injections have been associated 
with specific structural joint damage that may or may not be related 
to steroid treatment. There is a need for research to determine wheth-
er there is a risk for damage to joints as the result of IACS injections.
Essentials
 n Intra-articular corticosteroid (IACS) injections are recommended 
for pain management of hip and knee osteoarthritis (OA) in pa-
tients who have not responded to oral or topical analgesics.
 n Recent case series suggested that negative structural outcomes 
including accelerated OA progression, subchondral insufficiency 
fracture, complications of pre-existing osteonecrosis, and rapid 
joint destruction including bone loss may be observed after IACS 
injections.
 n To our knowledge, there are no studies with mid- to long-term 
follow-up available that provide data from before and after IACS 
injection compared with appropriate control participants.
 n Estimates of the prevalence of IACS injection-induced structural 
problems are highly variable.
 n As of today, there is no established recommendation or consensus 
regarding imaging, clinical, or laboratory markers before an IACS 
injection to screen for OA-related imaging abnormalities.
and a minority also developed joint surface collapse (9). To our 
knowledge, there are no analyses of large observational cohorts or 
prospective randomized controlled studies with mid- to long-term 
follow-up available that provide data from before and after IACS 
injection and compare patients undergoing injection to patients 
not undergoing injection or undergoing injection with a differ-
ent agent with similar levels of disease activity and severity. Such a 
controlled study is required to adequately address confounding by 
indications. On the basis of the observations available to date, no 
conclusions can be drawn regarding causality because it is uncer-
tain whether the described findings or events were already present 
at the time of injection.
The aim of this expert panel report is to review the current 
understanding of pain in OA, summarize current international 
guidelines regarding indications for IACS injection, and con-
sider potential preinterventional safety measures, including 
imaging. The interdisciplinary expert panel was composed of 
international experts in the field of rheumatology, orthopedics, 
epidemiology, and radiology who have been actively involved in 
clinical application and research regarding IACS injection (Ap-
pendix E1 [online]). Potential profiles of those who likely will 
benefit from the intervention and a suggestion for an updated 
patient consent form are presented. Points to consider regarding 
future radiologic and clinical research agendas are discussed.
OA Pain
The primary impact of OA is through its contribution to 
pain, which is often the primary driver for patients seeking 
medical care. The pain experienced in OA evolves over time 
with early stages accompanied by intermittent activity-related 
or weight-bearing pain, whereas later stages are accompanied 
by more constant pain that may be punctuated by intermit-
Figure 1: Osteoarthritis Research Society International (OARSI), American Col-
lege of Rheumatology (ACR), European League Against Rheumatism (EULAR), and 
the American Association of Orthopedic Surgeons (AAOS) recommendations for 
intra-articular corticosteroid injections.
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recommendations of the American Association of Orthopedic 
Surgeons, which were inconclusive (23). This position reflects 
the panel’s finding a lack of compelling evidence for or against 
IACS injection as treatment for knee OA. The American As-
sociation of Orthopedic Surgeons Expert Panel suggests that, 
in the face of their inconclusive recommendation, clinicians 
should base treatment decisions on clinical judgement and pa-
tient preference (23).
Recommendations for Hip OA
These societies’ stances on IACS injections are less cohesive re-
garding hip OA. The American College of Rheumatology and 
American Association of Orthopedic Surgeons recommended 
IACS injections for treatment of hip OA with the American 
College of Rheumatology stipulating that US guidance is pre-
ferred, whereas European League Against Rheumatism and 
Osteoarthritis Research Society International did not recom-
mend IACS hip injections (18–20,24,25). The American Col-
lege of Rheumatology’s strong recommendation in favor of 
IACS injections is specific to patients who did not respond to 
nonsteroidal anti-inflammatory drugs (19,20). The American 
Association of Orthopedic Surgeons recommendation is not 
contingent on US guidance; however, American Association of 
Orthopedic Surgeons guidelines specify that IACS injections 
should only be used for short-term treatment of hip OA (25). 
In explaining the decision not to recommend IACS hip injec-
tions, Osteoarthritis Research Society International guidelines 
cited insufficient scientific support of their efficacy (18).
Prediction of Treatment Response
IACS injections are used widely for knee OA but in 20%–30% 
of patients they are ineffective in reducing knee pain, even tran-
siently (26). For hip OA, IACS injections lead to a reduction 
thopedic Surgeons, American College of Rheumatology, Eu-
ropean League Against Rheumatism, and Osteoarthritis Re-
search Society International—are considered here (Fig 1). The 
American Association of Orthopedic Surgeons and American 
College of Rheumatology are the preeminent societies for or-
thopedic and rheumatology professionals, respectively, in the 
United States and are also recognized globally. The European 
League Against Rheumatism is the European equivalent of 
American College of Rheumatology, representing rheumatol-
ogy professionals throughout Europe, and the Osteoarthritis 
Research Society International is an internationally recog-
nized OA research organization.
Recommendations for Knee OA
All four societies considered IACS injection in the knee in 
their OA treatment guidelines (18–21). Both the Ameri-
can College of Rheumatology and European League Against 
Rheumatism recommend IACS injection as treatment of pa-
tients with knee OA, citing evidence of short-term pain relief 
(19–22). The American College of Rheumatology guidelines 
stipulate that IACS injection should be reserved for those who 
do not respond to nonsteroidal anti-inflammatory drugs and 
acetaminophen (19,20). The recommendation from the Euro-
pean League Against Rheumatism is specific to patients with 
acute pain exacerbations, especially in the context of effusion 
(21,22). The Osteoarthritis Research Society International 
guidelines also supported IACS injection for treatment of knee 
OA through a conditional recommendation for patients with 
or without comorbid conditions (18). The conditionality of 
the Osteoarthritis Research Society International recommen-
dation reflects the quality and strength of scientific support in 
the clinical literature and the potential toxicities of IACS injec-
tion. Strength of support for IACS injection was weakest in the 
Figure 2: Subchondral insufficiency fracture in a 61-year-old woman with severe knee pain unrelated to trauma referred to radiology for intra-articular corticosteroid 
(IACS) injection. (a) Anteroposterior radiograph of the right knee obtained the day of the IACS injection shows mild osteoarthritis (OA) with small osteophytes of the lateral 
tibia and femur (arrows) and no joint space narrowing. (b) Coronal fat-suppressed proton density-weighted MRI performed 1 month after the IACS injection shows sub-
chondral insufficiency fracture (arrow) with extensive bone marrow edema of the lateral femoral condyle (*) and adjacent soft tissue edema. There is also a severe lateral 
meniscus extrusion (arrowhead). (c) Repeat radiograph of the right knee 3 months later shows the subchondral insufficiency fracture with collapse of the articular contour 
of the lateral femoral condyle (arrow) surrounded by bone sclerosis (*) and lateral tibiofemoral joint space narrowing (arrowhead) likely secondary to the severe lateral 
meniscal subluxation. A normal or mild OA baseline radiograph in a patient with severe joint pain as in this case should trigger a preprocedural MRI to depict occult find-
ings of clinical relevance such as subchondral insufficiency fracture.
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was a significant positive interaction between severe 
pain at baseline (ie, 70 on a 0–100 scale) and the 
treatment effect of IACS injection compared with 
placebo, with a larger reduction in short-term pain 
(ie, up to 4 weeks). Two additional large studies, 
each with over 100 patients administered IACS, ex-
amined factors affecting response. In one of these 
studies (32), the rate of response at 3 months varied 
depending on whether it was assessed as a greater 
than 50% reduction in the Western Ontario and 
McMaster Universities OA Index pain scale (only 
16% of patients) or as a greater than 50% reduction 
in visual analog scale pain (39% of patients). Note 
that the percentage of persons responding to IACS 
injection was high in the weeks after the injection 
and falls by 3 months (33). Factors that lowered the 
likelihood of response at 3 months were worse ra-
diographic severity, limited range of motion, and 
more tenderness at the knee. In the largest study 
of factors affecting response to steroids, Maricar et 
al (26) studied 199 patients who were administered 
injections and examined their response at 2 weeks 
and 6 months. Twenty-seven percent of patients 
had no Outcome Measures in Rheumatology–Os-
teoarthritis Research Society International response 
at 2 weeks. Those with a lower likelihood of even 
short-term response included persons with no joint 
line tenderness and those with a history of ligament 
or meniscus injury. Twenty percent were character-
ized as longer-term responders. Factors associated with lack of 
long-term response were chronic widespread pain and depres-
sive symptoms, highlighting the need for understanding mecha-
nisms underlying an individual’s pain experience to tailor the 
appropriate therapy toward those mechanisms. In a study that 
examined the relation of synovial fluid white blood cell count to 
pain reduction after IACS injection, compared with those with 
a white blood cell count of less than or equal to 100 cells/mm3 
(referent), a greater within-person reduction in Knee injury and 
OA Outcome Score was observed in those with a white blood 
cell count between 101 and 250 cells/mm3 (b coefficient, 0.279, 
unstandardized coefficient of 11.1; 95% confidence interval: 
0.03, 22.17; P = .049) and 251–1000 cells/mm3 (b coefficient, 
0.320, unstandardized coefficient of 15.07; 95% confidence in-
terval: 2.06, 28.09; P = .024). That is, lower synovial fluid white 
blood count (albeit still within the normal range) was associated 
with a lower likelihood of response to IACS injection (34).
Regarding structural features, higher MRI meniscal damage 
(odds ratio, 0.74; 95% confidence interval: 0.55, 0.98), increas-
ing Kellgren and Lawrence maximal grade (odds ratio, 0.43; 
95% confidence interval: 0.23, 0.82), and joint space narrowing 
maximal score (odds ratio, 0.60; 95% confidence interval: 0.36, 
0.99) were each associated with a lower odds of longer term (~6 
months) responder status (35). Because the effects of IACS in-
jections generally last less than 3 months, analyses of 6 months 
outcome are likely examining the factors predicting OA pain 
rather than response to IACS injections. One study suggested that 
obese patients (body mass index  30 kg/m2) may be less likely to 
in pain at 3–4 weeks after injection compared with control pa-
tients on average, but the quality of evidence is limited (27,28). 
Identifying patients in whom treatment is likely to be ineffective 
would lessen the risk of adverse outcomes and would help avoid 
treatments that do not work. We will focus on knee OA because 
there are only sparse data available regarding the hip joint.
Several studies have attempted to identify factors that pre-
dict both short- and long-term response to IACS treatment in 
knee OA. Maricar et al (29) performed a systematic review of 
these studies that focused on the knee and found that it was 
challenging to summarize their findings. Studies varied in the 
following: how they defined response, the time during which 
they assessed response (short- vs long-term), the treatment used, 
and the factors evaluated that might predict response. Findings 
were inconsistent across studies, and many studies were small, 
which limited their ability to robustly identify predictors. The 
review suggested that response to IACS injections diminished 
with increasing severity of radiographic disease and increased 
with more severe knee pain. Knees without clinical effusions 
were less likely to respond. Another systematic review of IACS 
injection for knee or hip OA over the same period was not able 
to identify strong evidence that any potential predictors were as-
sociated with clinical response, including age, body mass index, 
depression, different corticosteroid preparations, radiographic 
grade, and clinical or sonographic evidence of inflammation or 
synovial hypertrophy (30). A meta-analysis (31) of individual 
patient data on the efficacy of IACS injection for knee or hip 
OA from seven randomized clinical trials reported that there 
Figure 3: Osteonecrosis in a 59-year-old man referred to radiology for intra-articular corti-
costeroid (IACS) injection. (a) Anteroposterior radiograph of the right knee shows severe osteo-
arthritis with bone on bone appearance (arrows) and large definite osteophytes (arrowheads). 
There is a subchondral sclerosis of the medial femoral condyle (*), which is expected in advanced 
osteoarthritis. No sign of subchondral insufficiency fracture or osteonecrosis. Patient was experienc-
ing an acute episode of pain exacerbation at time of presentation. (b) Coronal fat-suppressed 
intermediate-weighted MRI was performed before the IACS injection and discloses a large area of 
osteonecrosis of the medial femoral condyle (arrows) with pathognomonic serpiginous demarca-
tion and fat-equivalent center of lesion (*). No collapse of the articular contour is seen. There is 
attrition (ie, surface remodeling) as part of the advanced osteoarthritis process. IACS injection was 
not performed.
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guidance versus 77.8% without 
US guidance (39).
In summary, patients with 
greater pain at baseline, less se-
vere radiographic disease, and 
clinically apparent knee effu-
sion may be more likely to have 
symptom relief. In addition, the 
use of image-guided injection 
may increase the likelihood of 
a treatment response to IACS 
injection.
Minimizing Potential 
Adverse Events on the 
Basis of Imaging
Four radiologic entities have 
been reported after IACS injec-
tions of the knees and hips with 
a combined frequency of 8% in 
a recent noncontrolled case se-
ries of 459 IACS injections of 
the knee or hip (8,9), as follows: 
(a) rapid progressive OA (also 
termed accelerated OA) type 1 
is defined on the basis of rapid 
loss of joint space on radio-
graphs beyond the expected rate 
(ie, joint space loss of . 2 mm 
within a 12-month period [40]); 
(b) rapid progressive OA type 2 
is defined as rapid articular de-
struction with accelerated bone 
loss not typically observed in 
patients with OA in a 12-month 
period (41); (c) complication of 
osteonecrosis, which is associ-
ated with subchondral femoral 
bone plate collapse and devel-
opment of secondary OA; and 
(d) subchondral insufficiency 
fracture of the knee and hip, oc-
cult on radiographs at early stages and only recognized on MRI 
scans, which shows a subchondral hypointense fracture line of 
varying thickness and extent. A threshold of 4-mm thickness 
and/or 14 mm or more maximum length of the subchondral 
hypointense fracture line are considered relevant to define a 
negative outcome (ie, joint collapse) (42). There is an associated 
marked surrounding bone marrow edema that is more intense 
than would be expected for typical OA (8). Figures 2–5 show 
image examples of these radiologic entities from patients with 
OA who were referred to radiology for IACS injections. To our 
knowledge, it is not known whether these findings predated the 
IACS or were somehow induced by the IACS injection.
Given these four putative negative structural outcomes that 
have been reported in the context of IACS injections, the ques-
tion arises regarding whether preinterventional imaging is able 
experience symptom relief with IACS injection (36). In patients 
with a clinically apparent knee effusion and moderate knee pain, 
there was a significant association between larger synovitis volume 
on contrast material–enhanced MRI and greater pain relief, re-
flected in Knee Injury and OA Outcome Score pain subscale after 
IACS injection, although synovial tissue volume accounted for 
only a small proportion of the variance in change in pain (37).
One reason for inefficacy of steroid injections may be that 
some injections are inaccurately placed and outside the joint. Two 
reviews reported that US-guided IACS injections had superior 
efficacy to anatomic landmark-guided injections for accuracy of 
the injection placement and symptom relief (38,39). The accu-
racy of injection ranged from 63% to 100% with US, whereas 
the accuracy ranged from 39% to 100% with injections that were 
not guided with imaging (38,39). Accuracy was 95.8% with US 
Figure 4: Rapid progressive osteoarthritis (RPOA) type 1 in a 52-year-old man referred to radiology for intra-articular 
corticosteroid (IACS) injection. (a) Anteroposterior radiograph of the right knee shows mild osteoarthritis with definite os-
teophytes (arrows) and minimal joint space narrowing of the medial tibiofemoral joint (arrowheads). (b) Baseline coronal 
fat-suppressed intermediate-weighted MRI scan confirms the osteophytes (black arrows) and shows diffuse cartilage loss 
at the medial femoral condyle (white arrow) with moderate subluxation of the medial meniscus (arrowhead). (c) Six months 
after the IACS injection, a repeat anteroposterior radiograph of the right knee shows severe medial tibiofemoral joint space 
narrowing (arrows) with loss of more than 2 mm of joint space width consistent with rapid progressive osteoarthritis type 1. 
(d) Coronal fat-suppressed intermediate-weighted MRI scan confirms extensive loss of cartilage at the medial femur and 
tibia (white arrows) and worsening of the medial meniscal subluxation (arrowhead). There is also subchondral bone marrow 
edema at the medial tibia and femur (black arrows).
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In summary, certain patient characteristics, including but not 
limited to, acute change in pain not explained by a radiograph 
and no or only mild OA on a weight-bearing radiograph, should 
lead to careful reconsideration of planned IACS injection. In 
these circumstances, an MRI may be helpful to further evaluate 
the actual cause of pain (eg, subchondral insufficiency fracture, 
osteonecrosis, transient migratory osteoporosis, or occult stress 
fracture or reaction). However, if these are rare occurrences, 
such a strategy would be inefficient and cost prohibitive because 
screening vast numbers before IACS injection at MRI would be 
infeasible. Further, whether other strategies, such as counseling 
regarding weight bearing and/or physical therapy to minimize 
abnormal load through the joint postprocedure may help miti-
gate any risk is, to our knowledge, not known.
In Figure 7 the radiologist authors present a pragmatic pre-
procedural imaging algorithm from a radiologic perspective that 
may help recognize and potentially reduce adverse outcomes af-
ter IACS injection. We acknowledge that obtaining repeated ra-
diographs before repeated IACS injections was not supported by 
the participating orthopedist and rheumatologists of this panel. 
Whether these concerns are limited to observations related to 
IACS injections only, or more broadly to other agents, such as 
intra-articular injection of hyaluronic acid, is not clear.
What Do We Need to Include in the Patient 
Consent on the Basis of What We Know?
As of now, clinicians typically tell the patients, “even if IACS in-
jection does not help you with symptomatic relief, at least it will 
not harm you.” On the basis of clinical observations, this may not 
be true for some patients. In addition to standard risks for short-
term (or early) complications (eg, bleeding, infection, damage 
to reduce the occurrence of such events. By identifying these 
adverse joint findings, one could avoid administering IACS in-
jection to a joint that may already be at risk for further deterio-
ration. Currently, to our knowledge, there is no recommenda-
tion for imaging before administering IACS injection to detect 
such entities that may be regarded as so-called at-risk findings 
before the intervention. Subchondral insufficiency fracture and 
osteonecrosis are only rarely detectable on a radiograph, and 
the imaging findings are usually subtle or even occult, espe-
cially early in the process of these diseases. Administering an 
IACS injection in the presence of a subchondral insufficiency 
fracture may result in marked decrease in pain, and potentially 
result in increased weight bearing. As a consequence, the sub-
chondral insufficiency fracture may progress to an osteochon-
dral defect or frank articular joint collapse. If the underlying 
cause of pain is not known and patients who are referred for 
IACS injection exhibit no or only mild OA on a radiograph, 
the indication for IACS injection should be closely scrutinized 
as the cause of pain may be a process other than OA. Patients 
with a diagnosis of already collapsed osteonecrosis could likely 
be considered candidates for IACS injection, given that joint 
replacement would be their only other treatment option to 
relieve pain and no further damage to the joint is expected. 
A patient with femoral head osteonecrosis without collapse, 
however, may be at potential risk for collapse, which should be 
explained and carefully considered before intervention (Fig 6). 
We acknowledge that the evidence supporting such aggrava-
tion is anecdotal. Further, these types of injuries of the hip have 
been reported at least in case series in the literature, whereas 
virtually no such reports exist regarding the knee. Thus, obser-
vations from the hip should not be extrapolated to the knee.
Figure 5: Rapid progressive osteoarthritis type 2 in a 38-year-old woman referred to radiology for intra-articular corticosteroid (IACS) injec-
tion. (a) Baseline anteroposterior radiograph of the left hip shows mild osteoarthritis with small definite osteophytes at the lateral acetabulum and 
femoral head (arrows) and no definite joint space narrowing. (b) Six months after the IACS injection a repeat anteroposterior radiograph of the 
left hip shows a complete collapse of the head of the femur with marked bone loss of the femoral head (arrow) and surface remodeling and flat-
tening of the acetabulum (arrowheads). (c) Coronal fat-suppressed proton density-weighted MRI scan obtained on the same day demonstrates 
diffuse bone marrow edema of the femur and acetabulum (black and white *) and a large hip joint effusion (#) reflecting an ongoing process of 
marked synovial activation.
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attention and potentially also 
imaging follow-up.
Future Research Agenda
Given the paucity of effective 
and tolerable analgesic therapies 
for OA, we need to optimize the 
usefulness of IACS injections 
while minimizing potential tox-
icity. This prompts a number of 
questions about this commonly 
used therapy: How effective are 
the IACS injections? What fre-
quency should they be admin-
istered and for how long? What 
patient factors predict efficacy? 
What type of risks are associ-
ated with IACS injections and 
how likely are they? Who is at 
greatest risk for possible safety 
events? Can risk be attenuated 
with pre-IACS injection imag-
ing or radiographs? Are there 
any other means of risk miti-
gation, such as through opti-
mizing joint biomechanics or 
minimizing weight bearing after 
treatment? Are there potential 
risks with other intra-articular 
injections? Are there potential 
risks with joint pain relief more 
generally? Any potential studies 
addressing these questions will 
need large numbers and long 
duration.
Vast clinical experience of 
people who are administered 
repeat injections into a given 
joint do not suggest that im-
mediate structural deleterious 
effects are common and worsening of symptoms in a short 
time period is also uncommon. The trial by McAlindon et al 
(17) and the multiple trials of extended release triamcinolone 
for knee OA support these statements. In a matched-cohort 
study embedded in the larger OA Initiative study, following 
knee OA patients over 4 years, rapid progressive OA and osteo-
necrosis were not reported (43). It is possible that some people 
presenting with apparent OA knee pain have a subchondral 
insufficiency fracture as the cause of their pain. These lesions 
may represent part of the structural spectrum of OA pathology 
that includes bone marrow edema (and may be more common 
than currently understood to be). Currently we believe many 
subchondral insufficiency fractures heal over time with non-or 
protected weight-bearing for at least 6 weeks (8). It is unclear 
if IACS injection interferes with healing, or if it helps the pain 
of subchondral insufficiency fracture without negative effects 
on fracture healing.
to intra-articular and periarticular structures along the needle 
path, joint pain, swelling, and stiffness) we also need to explain 
to the patients that possible longer-term (or delayed) events may 
occur that may or may not be related to the actual IACS injec-
tion. Such complications may include, but are not limited to, 
accelerated OA progression (ie, rapid progressive OA type 1), 
subchondral insufficiency fracture leading potentially to artic-
ular collapse, osteonecrosis (also leading to articular collapse), 
and rapid joint destruction with bone loss (ie, rapid progressive 
OA type 2). According to a single institution report, these joint 
events can occur in up to 10% of patients after IACS injection 
in the hip and to a lesser extent in the knee joint (8). Whether 
these findings were apparent or already ongoing preinjection is 
not known. Thus, in addition to explaining the above potential 
risks at the time of informed consent, it will also be important 
to advise the patient that should they experience worsening joint 
pain after IACS injection, they should immediately seek clinical 
Figure 6: Osteonecrosis in a 29-year-old man who presented with right hip pain. (a) Anteroposterior radiograph and 
(b) coronal fat-suppressed proton density-weighted MRI of the right hip obtained on the same day show osteonecrosis in 
the right femoral head, with preserved femoral head contours (arrows). He subsequently went to the sports medicine clinic 
and was administered a right hip joint intra-articular corticosteroid (IACS) injection for pain. Three months later, he was 
referred to our institution for repeat IACS injection due to worsening pain. (c) Repeat anteroposterior right hip radiograph 
shows collapse of the superior femoral head articular surface (arrows). (d) Coronal reformatted CT image of the right hip 
confirms the collapse of the superior femoral head articular surface (arrows) and shows new hip joint space narrowing. Pa-
tient subsequently underwent right hip joint replacement.
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tissues, such as cartilage and bone, are related to drug and im-
portantly whether this association is causal or whether there 
is another underlying causal factor relating to both pain and 
structural progression.
Should There Be Imaging before Steroid Injections?
IACS injections have been associated with specific structural 
pathology that may or may not be related to steroid treatment 
versus pre-existing pathology that caused symptoms leading to 
IACS injection. To develop a rational clinical policy regarding 
the advisability of preprocedure radiographs we need to un-
derstand the prevalence of these radiographic findings be-
fore and after IACS injections compared with persons with 
similar disease severity who did not undergo an injection 
or who were administered another injection (eg, hyaluronic 
acid), whether there are patient factors associated with these 
findings, and the formal cost effectiveness of screening. 
These inputs would provide the rationale for a trial of ra-
diographic screening before IACS injections. We recognize 
that this research agenda will require substantial funding 
In terms of efficacy, we need to understand the benefits of re-
peat injections. There is a question as to whether IACS injections 
lose their efficacy over time (17,33). The trial by McAlindon and 
colleagues assessed pain at 3-month intervals (before next injec-
tion). Because the analgesic effect of injections tends to last less 
than 3 months, this trial cannot determine if patients experienced 
similar pain relief after multiple injections (17,33). An observa-
tional, two-injection study that used extended-release triamcino-
lone acetate showed that the second injection lasted as long as the 
first (44). We will need carefully designed randomized clinical tri-
als to better understand the benefits of multiple injections.
Currently, the estimates on prevalence of IACS injections–
induced structural problems are highly variable. The trial by 
McAlindon et al (17) demonstrated a small effect on cartilage 
and it is unclear how this translates to clinical end points such 
as pain severity, functional limitations, or joint replacement. 
Further, it is unknown how many patients have avoided total 
knee replacement by judicious use of IACS injections over 
many years, so long-term studies with sensitive MRI end 
points are required to determine if effects on pertinent joint 
Figure 7: Suggestion of the use of imaging in the context of intra-articular corticosteroid (IACS) injection (to be tested for efficacy and cost-effectiveness). (a) First IACS 
injection and (b) repeat IACS injection. Obtaining weight-bearing imaging prior to repeat IACS injection is not supported by rheumatologists and orthopedic surgeons on 
the panel. OA = osteoarthritis, SIF = subchondral insufficiency fracture, RPOA = rapid progressive OA.
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and many years. If these complications are rare, were already 
present as causes of pain before the injection, or would have 
occurred irrespective of the intervention, then preinjection 
imaging would not be needed (45).
Conclusion
In summary, intra-articular corticosteroid (IACS) injection is 
a commonly performed procedure for pain relief in patients 
with knee or hip osteoarthritis (OA) in an outpatient setting. 
To our knowledge, there is no established recommendation 
or consensus regarding imaging before an IACS injection to 
screen for OA-related imaging abnormalities. It may be im-
portant to identify a subchondral insufficiency fracture before 
IACS injection because glucocorticoids may inhibit the heal-
ing process of such a fracture (46). However, the prevalence 
of subchondral insufficiency fracture is unknown and, if it is 
rare, screening for subchondral insufficiency fracture before 
an IACS injection would likely not be cost effective.
When patients with no radiographic OA or only mild radio-
graphic OA are referred for IACS injection to achieve pain relief, 
the indication for IACS injection should potentially be ques-
tioned. Limited literature evidence has indicated that some pa-
tients who show a rapid decrease in joint space width or articular 
surface destruction with or without bone loss tend to have no 
radiographic OA or only mild OA at initial presentation, likely 
because there was an already-ongoing, underlying, non-OA re-
lated process present at that time (47).
To conclude, the exact causality and natural history of these 
articular complications are unclear and warrant further study. 
To do so, large prospective studies (optimally double-blind 
clinical trials) evaluating the natural history of accelerated OA 
or joint destruction in OA and after IACS injections would 
be ideal. Performing preinjection joint radiographs to identify 
patients with no or mild radiographic OA may be needed but 
that depends on the prevalence of these abnormalities and the 
likelihood of developing adverse outcomes. Additional imaging 
such as MRI may be helpful to further evaluate the actual cause 
of pain (especially acute pain) before a planned injection, with 
the recognition that there is often a structure-symptom discor-
dance that makes it challenging to ascribe pain to particular 
image-based pathology. Further, as with preprocedural radio-
graphic imaging, if these findings are rare, additional MRI will 
be prohibitively costly. Providers and patients need to continue 
engaging in shared decision making regarding IACS injections. 
To better inform such provider-patient communications and 
aid treatment decisions, the true prevalence of pathology, their 
relation to IACS injections or other OA treatments, and best 
risk mitigation strategies require urgent study.
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